DelveInsight has launched a new report on Antibody-Mediated Rejection Epidemiology
About Antibody-Mediated Rejection
Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation. In the continuum of allograft rejection, the development of antibodies plays a critical role, and antibodies are considered a major cause of allograft failure.
Antibody-Mediated Rejection Epidemiology
Antibody-mediated rejection (AMR) is a major cause of late kidney transplant failure. Although hyperacute (i.e. preformed antibody-mediated) rejection has been recognized since the 1960s, the role of antibodies in other forms of rejection was not clear until new diagnostic methods became available. The knowledge about the role of antibodies in allograft rejection, particularly in some forms of chronic allograft rejection, has been evolving rapidly over the last decade.
Important facts of Antibody-Mediated Rejection Epidemiology report
Download free sample copy of Antibody-Mediated Rejection Epidemiology report- https://www.delveinsight.com/sample-request/antibody-mediated-graft-rejection-epidemiology-forecast
Antibody-Mediated Rejection Epidemiology Segmentation
Antibody-Mediated Rejection Prevalent Population
The incidence of acute and chronic AMR was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR. With respect to diagnosis and follow-up, sensitive biomarkers that reflect disease activity, also during smouldering disease, are needed.
Antibody-Mediated Rejection Epidemiology: Report Scope
Following is the table of content of Antibody-Mediated Rejection epidemiology report
1. Key Insights
2. Executive Summary of Antibody-Mediated Graft Rejection
3. Antibody-Mediated Graft Rejection: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
What are the important reasons to buy this report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/